BRIEF-Lundbeck and Otsuka expand collaboration on schizophrenia drug

COPENHAGEN, March 7 Thu Mar 7, 2013 1:10am EST

Related Topics

COPENHAGEN, March 7 (Reuters) - Lundbeck A/S : * Says Otsuka and Lundbeck expand their existing collaboration * Says collaboration to include promotion of Abilify swallowable tablets, oral

solution, orally-disintegrating tablets and the intramuscular rapid

injectable in 14 European countries. * A once-monthly injectable form of Abilify, will be co-promoted by Otsuka and Lundbeck in the U.S. and will start becoming available there from March 18. * The drug was approved for use in schizophrenia by the U.S. FDA (Food and Drug Administration) on February 28.

FILED UNDER:
Comments (0)
This discussion is now closed. We welcome comments on our articles for a limited period after their publication.